Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Change in Account Payables (2021 - 2025)

Aligos Therapeutics' Change in Account Payables history spans 5 years, with the latest figure at -$669000.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 295.86% year-over-year to -$669000.0; the TTM value through Dec 2025 reached $1.4 million, up 2512.96%, while the annual FY2025 figure was $1.4 million, 2512.96% up from the prior year.
  • Change in Account Payables reached -$669000.0 in Q4 2025 per ALGS's latest filing, down from $752000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $4.0 million in Q2 2024 to a low of -$4.1 million in Q3 2024.
  • Average Change in Account Payables over 5 years is $32750.0, with a median of $0.0 recorded in 2022.
  • The largest YoY upside for Change in Account Payables was 849.16% in 2024 against a maximum downside of 1259.67% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at $399000.0 in 2021, then surged by 352.63% to $1.8 million in 2022, then crashed by 123.42% to -$423000.0 in 2023, then soared by 60.05% to -$169000.0 in 2024, then plummeted by 295.86% to -$669000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Change in Account Payables are -$669000.0 (Q4 2025), $752000.0 (Q3 2025), and -$402000.0 (Q2 2025).